AB Science S.A. (EPA:AB)
France · Delayed Price · Currency is EUR 0.9410
+0.0110 (1.18%)
Jun 3, 2026, 4:39 PM CET
AB Science Employees
AB Science had 36 employees as of June 30, 2025.
Employees
36
Change
n/a
Growth
n/a
Revenue / Employee
€32,611
Profits / Employee
€43,250
Market Cap
71.18M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 36 | - | - | 36 | 0 |
| Dec 31, 2024 | 39 | -18 | -31.58% | 28 | 11 |
| Dec 31, 2023 | 57 | -46 | -44.66% | 51 | 6 |
| Dec 31, 2022 | 103 | 5 | 5.10% | 103 | 0 |
| Dec 31, 2021 | 98 | 6 | 6.52% | 98 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 155,975 |
| Sanofi | 74,846 |
| Sartorius Stedim Biotech | 10,456 |
| Ipsen | 5,535 |
| Eurofins-Cerep | 207 |
| Klea Holding | 128 |
| Adocia | 80 |
| OSE Immunotherapeutics | 64 |
AB Science News
- 22 hours ago - AB Science : Stonegate Capital Partners updates its coverage of AB Science's stock with a target price of EUR 4.25 per share - GlobeNewsWire
- 8 days ago - AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share - GlobeNewsWire
- 20 days ago - AB Science reports its revenues for the year 2025 and provides an update on its activities - GlobeNewsWire
- 20 days ago - AB Science Earnings release: H2 2025 - Filings
- 5 weeks ago - AB Science announces the successful completion of a EUR 3.2 million private placement - GlobeNewsWire
- 5 weeks ago - AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors - GlobeNewsWire
- 6 weeks ago - AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients - GlobeNewsWire
- 6 weeks ago - AB Science provides an update on its clinical development program. - GlobeNewsWire